EHA: European Hematology Association

Conference Coverage

Drug proves active in resistant MM

STOCKHOLM—The alkylating peptide melflufen has demonstrated activity in patients with treatment-resistant multiple myeloma (MM). In a phase 2...

Conference Coverage

‘Very encouraging’ results in BPDCN

STOCKHOLM—Tagraxofusp (SL-401) has produced “very encouraging” results in a phase 2 trial of patients with blastic plasmacytoid dendritic cell...

Conference Coverage

Voxelotor benefits adolescents with SCD

STOCKHOLM—An ongoing phase 2 study suggests voxelotor (GBT440) can benefit adolescents with sickle cell disease (SCD). In the HOPE-KIDS 1 study,...

Conference Coverage

Survey reveals patient perceptions of ITP

STOCKHOLM—A new survey has revealed patients’ perceptions of immune thrombocytopenia (ITP) and how the condition impacts their quality of life (...

Pages